Imaging cardiac SCN5A using the novel F-18 radiotracer radiocaine

[1]  S. Cook,et al.  The Diagnosis and Evaluation of Dilated Cardiomyopathy. , 2016, Journal of the American College of Cardiology.

[2]  Katherine C. Wu,et al.  Arrhythmia risk stratification of patients after myocardial infarction using personalized heart models , 2016, Nature Communications.

[3]  Eric T. Wang,et al.  Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy , 2016, Nature Communications.

[4]  H. Wey,et al.  PET Neurochemical Imaging Modes. , 2016, Seminars in nuclear medicine.

[5]  A. Wilde,et al.  The cardiac sodium channel gene SCN5A and its gene product NaV1.5: Role in physiology and pathophysiology. , 2015, Gene.

[6]  K. Kwong,et al.  Voltage-gated sodium channels. , 2015, Current opinion in pharmacology.

[7]  Li Xie,et al.  Whole-exome sequencing identifies Y1495X of SCN5A to be associated with familial conduction disease and sudden death , 2014, Scientific Reports.

[8]  Dan M Roden,et al.  Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death , 2013, Nature Genetics.

[9]  J. Galpin,et al.  Molecular basis for class Ib anti-arrhythmic inhibition of cardiac sodium channels. , 2011, Nature communications.

[10]  W. R. Taylor,et al.  Human Heart Failure Is Associated With Abnormal C-Terminal Splicing Variants in the Cardiac Sodium Channel , 2007, Circulation research.

[11]  W. Giles,et al.  Dilated cardiomyopathy is associated with reduced expression of the cardiac sodium channel Scn5a. , 2007, Cardiovascular research.

[12]  B. Bean.  The action potential in mammalian central neurons , 2007, Nature Reviews Neuroscience.

[13]  C. H. Conrad,et al.  Studies of Prevention, Treatment and Mechanisms of Heart Failure in the Aging Spontaneously Hypertensive Rat , 2004, Heart Failure Reviews.

[14]  P. Kowey,et al.  Pharmacological effects of antiarrhythmic drugs. Review and update. , 1998, Archives of internal medicine.

[15]  A. George,et al.  Characterization of human cardiac Na+ channel mutations in the congenital long QT syndrome. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R Horn,et al.  Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Taouis,et al.  Aminoalkyl structural requirements for interaction of lidocaine with the class I antiarrhythmic drug receptor on rat cardiac myocytes. , 1991, Molecular pharmacology.

[18]  H. Motulsky,et al.  Calculating receptor number from binding experiments using same compound as radioligand and competitor. , 1989, Trends in pharmacological sciences.

[19]  M D Blaufox,et al.  Blood volume in the rat. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  D. Harrison,et al.  The Clinical Pharmacology of Lidocaine as an Antiarrhythymic Drug , 1974, Circulation.

[21]  R. Méndez,et al.  Cardiac pharmacology. , 1970, Annual review of pharmacology.